Maria Cellerino1, Federico Ivaldi1, Matteo Pardini1, Gianluca Rotta1, Gemma Vila1, Priscilla Bäcker-Koduah1, Tone Berge1, Alice Laroni1, Caterina Lapucci1, Giovanni Novi1, Giacomo Boffa1, Elvira Sbragia1, Serena Palmeri1, Susanna Asseyer1, Einar Høgestøl1, Cristina Campi1, Michele Piana1, Matilde Inglese1, Friedemann Paul1, Hanne F Harbo1, Pablo Villoslada1, Nicole Kerlero de Rosbo1, Antonio Uccelli2. 1. From the Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (M.C., F.I., M.P., A.L., C.L., G.N., G.B., E.S., S.P., M.I., N.K.d.R.) and Center of Excellence for Biomedical Research (A.U.), University of Genoa, Italy; BD Biosciences Italy (G.R.), Milan; Institut d'Investigacions Biomediques August Pi Sunyer (G.V., P.V.), Barcelona, Spain; Charité Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine (P.B.-K., S.A., F.P.), Germany; Department of Research, Innovation and Education (T.B.), Neuroscience Research Unit, Oslo University Hospital; Department of Mechanical Electronics and Chemical Engineering (T.B.), Oslo Metropolitan University, Norway; University of Oslo (E.H., H.F.H.) and Oslo University Hospital (H.F.H.), Norway; Department of Mathematics and Padova Neuroscience Center (C.C.), University of Padua, Italy; Department of Mathematics (M.P.), University of Genoa, Italy; and IRCCS Ospedale Policlinico San Martino (A.L., M.P., M.I., A.U.), Genoa, Italy. 2. From the Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (M.C., F.I., M.P., A.L., C.L., G.N., G.B., E.S., S.P., M.I., N.K.d.R.) and Center of Excellence for Biomedical Research (A.U.), University of Genoa, Italy; BD Biosciences Italy (G.R.), Milan; Institut d'Investigacions Biomediques August Pi Sunyer (G.V., P.V.), Barcelona, Spain; Charité Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine (P.B.-K., S.A., F.P.), Germany; Department of Research, Innovation and Education (T.B.), Neuroscience Research Unit, Oslo University Hospital; Department of Mechanical Electronics and Chemical Engineering (T.B.), Oslo Metropolitan University, Norway; University of Oslo (E.H., H.F.H.) and Oslo University Hospital (H.F.H.), Norway; Department of Mathematics and Padova Neuroscience Center (C.C.), University of Padua, Italy; Department of Mathematics (M.P.), University of Genoa, Italy; and IRCCS Ospedale Policlinico San Martino (A.L., M.P., M.I., A.U.), Genoa, Italy. auccelli@neurologia.unige.it.
Abstract
OBJECTIVE: To establish cytometry profiles associated with disease stages and immunotherapy in MS. METHODS: Demographic/clinical data and peripheral blood samples were collected from 227 patients with MS and 82 sex- and age-matched healthy controls (HCs) enrolled in a cross-sectional study at 4 European MS centers (Spain, Italy, Germany, and Norway). Flow cytometry of isolated peripheral blood mononuclear cells was performed in each center using specifically prepared antibody-cocktail Lyotubes; data analysis was centralized at the Genoa center. Differences in immune cell subsets were assessed between groups of untreated patients with relapsing-remitting or progressive MS (RRMS or PMS) and HCs and between groups of patients with RRMS taking 6 commonly used disease-modifying drugs. RESULTS: In untreated patients with MS, significantly higher frequencies of Th17 cells in the RRMS population compared with HC and lower frequencies of B-memory/B-regulatory cells as well as higher percentages of B-mature cells in patients with PMS compared with HCs emerged. Overall, the greatest deviation in immunophenotype in MS was observed by treatment rather than disease course, with the strongest impact found in fingolimod-treated patients. Fingolimod induced a decrease in total CD4+ T cells and in B-mature and B-memory cells and increases in CD4+ and CD8+ T-regulatory and B-regulatory cells. CONCLUSIONS: Our highly standardized, multisite cytomics data provide further understanding of treatment impact on MS immunophenotype and could pave the way toward monitoring immune cells to help clinical management of MS individuals.
OBJECTIVE: To establish cytometry profiles associated with disease stages and immunotherapy in MS. METHODS: Demographic/clinical data and peripheral blood samples were collected from 227 patients with MS and 82 sex- and age-matched healthy controls (HCs) enrolled in a cross-sectional study at 4 European MS centers (Spain, Italy, Germany, and Norway). Flow cytometry of isolated peripheral blood mononuclear cells was performed in each center using specifically prepared antibody-cocktail Lyotubes; data analysis was centralized at the Genoa center. Differences in immune cell subsets were assessed between groups of untreated patients with relapsing-remitting or progressive MS (RRMS or PMS) and HCs and between groups of patients with RRMS taking 6 commonly used disease-modifying drugs. RESULTS: In untreated patients with MS, significantly higher frequencies of Th17 cells in the RRMS population compared with HC and lower frequencies of B-memory/B-regulatory cells as well as higher percentages of B-mature cells in patients with PMS compared with HCs emerged. Overall, the greatest deviation in immunophenotype in MS was observed by treatment rather than disease course, with the strongest impact found in fingolimod-treated patients. Fingolimod induced a decrease in total CD4+ T cells and in B-mature and B-memory cells and increases in CD4+ and CD8+ T-regulatory and B-regulatory cells. CONCLUSIONS: Our highly standardized, multisite cytomics data provide further understanding of treatment impact on MS immunophenotype and could pave the way toward monitoring immune cells to help clinical management of MS individuals.
Authors: Sara J Ireland; Alyssa A Guzman; Dina E O'Brien; Samuel Hughes; Benjamin Greenberg; Angela Flores; Donna Graves; Gina Remington; Elliot M Frohman; Laurie S Davis; Nancy L Monson Journal: JAMA Neurol Date: 2014-11 Impact factor: 18.302
Authors: Aina Teniente-Serra; Laia Grau-López; M José Mansilla; Marco Fernández-Sanmartín; Anna Ester Condins; Cristina Ramo-Tello; Eva Martínez-Cáceres Journal: Autoimmunity Date: 2016-02-01 Impact factor: 2.815
Authors: Collin M Spencer; Elizabeth C Crabtree-Hartman; Klaus Lehmann-Horn; Bruce A C Cree; Scott S Zamvil Journal: Neurol Neuroimmunol Neuroinflamm Date: 2015-02-12
Authors: Berit Grützke; Stephanie Hucke; Catharina C Gross; Martin V B Herold; Anita Posevitz-Fejfar; Brigitte T Wildemann; Bernd C Kieseier; Thomas Dehmel; Heinz Wiendl; Luisa Klotz Journal: Ann Clin Transl Neurol Date: 2015-01-16 Impact factor: 4.511
Authors: James Dooley; Ine Pauwels; Dean Franckaert; Ide Smets; Josselyn E Garcia-Perez; Kelly Hilven; Dina Danso-Abeam; Joanne Terbeek; Anh T L Nguyen; Louis De Muynck; Brigitte Decallonne; Bénédicte Dubois; Adrian Liston; An Goris Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-05-10
Authors: Steven K Lundy; Qi Wu; Qin Wang; Catherine A Dowling; Sophina H Taitano; Guangmei Mao; Yang Mao-Draayer Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-03-03
Authors: Giancarlo Comi; Amit Bar-Or; Hans Lassmann; Antonio Uccelli; Hans-Peter Hartung; Xavier Montalban; Per Solberg Sørensen; Reinhard Hohlfeld; Stephen L Hauser Journal: Ann Neurol Date: 2020-11-04 Impact factor: 10.422
Authors: Priscilla Bäcker-Koduah; Carmen Infante-Duarte; Federico Ivaldi; Antonio Uccelli; Judith Bellmann-Strobl; Klaus-Dieter Wernecke; Michael Sy; Michael Demetriou; Jan Dörr; Friedemann Paul; Alexander Ulrich Brandt Journal: Ann Clin Transl Neurol Date: 2020-08-23 Impact factor: 4.511
Authors: Jan Dörr; Carmen Infante-Duarte; Svenja C Schwichtenberg; Anne Wisgalla; Maria Schroeder-Castagno; Cesar Alvarez-González; Stephan Schlickeiser; Nadja Siebert; Judith Bellmann-Strobl; Klaus-Dieter Wernecke; Friedemann Paul Journal: Neurotherapeutics Date: 2021-07-09 Impact factor: 7.620